AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34488858
Drug: Subcutaneous IVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IVM at 200 ?g/kg/48 h (Arm A)
Trial: 34488858
Drug: Subcutaneous IVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IVM at 200 ?g/kg/48 h and oral Zn 20mg/8 h (Arm B)
Trial: 34488858
Drug: Oral IVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral IVM at 0.2 mg/kg/day (Arm C)
Trial: 34488858
Drug: Oral IVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral IVM at 0.2 mg/kg/day and oral Zn 20mg/8 h (Arm D)
Trial: 34488858
Drug: Oral Zn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Zn 20mg/8 h (Arm E)
Trial: 33538345
Drug: Blue and
RxNorm normalized name: Aluminum Sesquichlorohydrate 0.17 mL in 1 mL TOPICAL LIQUID [CYZONE BLUE AND BLUE FOR HER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue and red light treatments consecutively on the same visit for 4 consecutive weeks
Trial: 33662124
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (12-day postoperative taper)
Trial: 34853102
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets
Trial: 32879954
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (NoTx)
Trial: 33485468
Drug: 3 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 µg with Algel-IMDG
Trial: 33485468
Drug: 6 µg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 µg with Algel-IMDG
Trial: 33485468
Drug: 6 µg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 µg with Algel
Trial: 32481440
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg/day
Trial: 36349973
Drug: Supplementary food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary food and anti-infective treatments
Trial: 34881370
Drug: Intranasal live
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal live attenuated influenza vaccine (LAIV) administered at enrolment (day 0)
Trial: 34881370
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (LAIV administered at the end of active follow-up, day 21)
Trial: 36428011
Drug: Control pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control pharmacotherapy trial
Trial: 38914694
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g glucose
Trial: 33284114
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of intradermal f-IPV (administered at 14 and 36 weeks)
Trial: 33284114
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of intramuscular IPV (administered at 14 and 36 weeks)
Trial: 33284114
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of intradermal f-IPV (administered at 10, 14, and 36 weeks)
Trial: 33284114
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of intramuscular IPV (administered at 10, 14, and 36 weeks)
Trial: 32022371
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral temazepam
Trial: 32588515
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg/day for 6 months plus celecoxib 200 mg/day for 3 months
Trial: 32588515
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg/day for 6 months
Trial: 34953184
Drug: Basic periodontal
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic periodontal therapy only
Trial: 33292916
Drug: Videoconference administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Videoconference administration of neuropsychological measures
Trial: 33292916
Drug: In-person administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person administration of neuropsychological measures
Trial: 36471186
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise training (CT)
Trial: 32496902
Drug: Intrathecal Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal Triple Therapy (ITT)
Trial: 34994794
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy modalities
Trial: 34789000
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive atraumatic restorative treatment and the Hall technique approaches (ART-HT)
Trial: 32126156
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Pain (CBT-P)
Trial: 32537740
Drug: Utilization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utilization of the ECG Belt to guide implant as well as postimplant programming
Trial: 36226977
Drug: Ruxolitinib 15
RxNorm normalized name: ruxolitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 15 mg
Trial: 36226977
Drug: Ruxolitinib 5
RxNorm normalized name: ruxolitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg
Trial: 33809796
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium meal plan (<0.95 mg/kcal)
Trial: 33809796
Drug: Typical sodium
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical sodium meal plan (>2 mg/kcal)
Trial: 32406601
Drug: Colesevelam 3.75
RxNorm normalized name: colesevelam 3.75 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.75 g daily
Trial: 37027137
Drug: Taking sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking sleep medications once or twice a week
Trial: 37027137
Drug: Taking sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking sleep medications less than once a week
Trial: 36229579
Drug: Repeat sequential
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat sequential two FLOX cycles and two immune checkpoint blockade (ICB) cycles
Trial: 35841234
Drug: Soticlestat (≤300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat (≤300 mg twice daily, weight-adjusted)
Trial: 34090216
Drug: Olive oil-based
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil-based intravenous lipid emulsion (OO-based IVLE)
Trial: 34090216
Drug: Soybean oil-based
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil-based intravenous lipid emulsion (SO-based IVLE)
Trial: 33988337
Drug: Standard-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose trivalent inactivated influenza vaccination (SDTIIV)
Trial: 33988337
Drug: Double-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose trivalent inactivated influenza vaccination (DDTIIV)
Trial: 33988337
Drug: Booster-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster-dose trivalent inactivated influenza vaccination (BDTIIV)
Trial: 36458916
Drug: Inhaled sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled sargramostim (125 mcg twice daily for 5 days)
Trial: 34940806
Drug: 20-Valent Pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-Valent Pneumococcal Conjugate Vaccine (PCV20)
Trial: 34940806
Drug: 13-Valent Pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
Trial: 34940806
Drug: 23-Valent Polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-Valent Polysaccharide Vaccine (PPSV23)
Trial: 39359014
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg twice daily for 3 months
Trial: 35766976
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity
Trial: 35972855
Drug: Islatravir 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 0.25 mg with doravirine and lamivudine
Trial: 35972855
Drug: Islatravir 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 0.75 mg with doravirine and lamivudine
Trial: 32006650
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue photodynamic therapy (MB-PDT) applied twice a week for four weeks
Trial: 32006650
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone valerate ointment 100 mg applied three times per day for four weeks
Trial: 35358428
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with artemether–lumefantrine plus amodiaquine
Trial: 35766202
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection (intra and periarticular) of methylprednisolone acetate 40 mg and local anesthetic
Trial: 35766202
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of methylprednisolone acetate 40 mg and local anesthetic
Trial: 33624730
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg body mass)
Trial: 34594197
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (manual pressure release of myofascial trigger points)
Trial: 35918731
Drug: Focused, expert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused, expert medication management intervention including in-person consultation and virtual care follow-up.
Trial: 34311606
Drug: Single alcoholic
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single alcoholic beverage administration (placebo 0.00%, low 0.03%, moderate 0.06%, high 0.09%)
Trial: 34311606
Drug: Cumulative alcoholic
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative alcoholic administration method (placebo followed by three alcoholic drinks)
Trial: 32279615
Drug: Topical silicone
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone gel plus herbal extract gel (Allium cepa, Centella Asiatica, Aloe vera and Paper Mulberry)
Trial: 32522282
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg x 1 for Day 1-3, 250 mg x 1 for Day 4-15) and Hydroxychloroquine (200 mg x 2 for Day 1-15)
Trial: 32522282
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + placebo
Trial: 33090733
Drug: BMS-986166 (0.75-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986166 (0.75-5.0 mg single dose and 0.25-1.5 mg/day repeated dose)
Trial: 33090733
Drug: BMS-986166 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986166 (0.5 mg/day)
Trial: 32080133
Drug: Routine surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine surgical treatment without 3D printing
Trial: 35603798
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) with compression therapy
Trial: 35603798
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + compression therapy alone
Trial: 33825020
Drug: Dental spray
RxNorm normalized name: Orasep Dental Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental spray
Trial: 33825020
Drug: Toothpaste gel
RxNorm normalized name: ProDenRx Gel Toothpaste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste gel
Trial: 33825020
Drug: Mouth rinsing
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth rinsing and spray application
Trial: 33859411
Drug: Deep learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning framework for analyzing Cytosponge-TFF3 test samples; specific dosage and duration not mentioned.
Trial: 35360551
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) treatment
Trial: 32781086
Drug: Aldafermin 1
RxNorm normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldafermin 1 mg daily for 24 weeks
Trial: 34649459
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic Acid (Aspirin)
Trial: 32237205
Drug: Gynecologic cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynecologic cancer patients pre-radiation therapy
Trial: 32237205
Drug: Gynecologic cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynecologic cancer patients post-radiation therapy
Trial: 33586087
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy with gustative‐thermic‐tactile stimulation (group A)
Trial: 34530882
Drug: Weekly SMS-questions
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly SMS-questions about pain frequency and pain intensity
Trial: 33079199
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 50% efficacy
Trial: 33079199
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 1 year protection duration
Trial: 33079199
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 1 in 10,000 major adverse effects
Trial: 33079199
Drug: Vaccine from
RxNorm normalized name: Human rabies vaccine from Chicken fibroblast culture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine from non-US country (China)
Trial: 33079199
Drug: Vaccine from
RxNorm normalized name: Human rabies vaccine from Chicken fibroblast culture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine from non-US country (UK)
Trial: 33079199
Drug: Vaccine from
RxNorm normalized name: Human rabies vaccine from Chicken fibroblast culture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine from China
Trial: 32019154
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (95 µg/day folate from vegetables)
Trial: 32019154
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (191 µg/day folate from vegetables)
Trial: 34902368
Drug: RT concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT concurrent with temozolomide (TMZ) (75 mg/m2/d, 7 d/week) followed by adjuvant TMZ (CRT group)
Trial: 34902368
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) alone (RT group, n = 18; 60 Gy in 30 daily fractions)
Trial: 34902368
Drug: RT concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT concurrent with temozolomide (TMZ) (CRT group)
Trial: 34447389
Drug: Correlation analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation analysis of antibody titres and carriage density for both pathogens.
Trial: 33094725
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (4 L/min)
Trial: 38619178
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel
Trial: 34558823
Drug: Lead-in TDF
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead-in TDF monotherapy
Trial: 34558823
Drug: TDF monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF monotherapy followed by NAP + pegIFN
Trial: 34558823
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of therapy
Trial: 34558823
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of therapy in 5 participants
Trial: 32331071
Drug: SEP-363856 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-363856 (50 or 75 mg/d)
Trial: 34836278
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum PS128 (PS128) treatment (LT) - 2 capsules (3 × 10^10 CFU/capsule) each morning and evening for 4 weeks
Trial: 34836278
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (PT) - 2 capsules for 4 weeks
Trial: 34836278
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum PS128 (PS128) treatment (LT)
Trial: 34836278
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (PT)
Trial: 36219046
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 1% QD for 21 days
Trial: 32003872
Drug: Long implants
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long implants (10 mm)
Trial: 32003872
Drug: Crown-to-implant ratio
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crown-to-implant ratio
Trial: 34262113
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma treatment
Trial: 33298342
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment regimens modified to reduce toxicity in older/senior patients; specific dosage and duration not mentioned.
Trial: 33298342
Drug: Geriatric assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric assessments to select older patients for rigorous treatment regimens; specific assessment methods not mentioned.
Trial: 32701199
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily (3 weeks on, 1 week off)
Trial: 35935309
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution 10 mL (Control)
Trial: 33909358
Drug: Rehabilitation robot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation robot rehabilitation training synchronizing acupuncture exercise therapy
Trial: 33909358
Drug: Acupuncture exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture exercise therapy (Control)
Trial: 36007871
Drug: Late evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Late evening snack and oral amino acid capsules (LES and OAA)
Trial: 32011196
Drug: A-PRP injections
RxNorm normalized name: PRPP
DrugBank: 5-O-phosphono-alpha-D-ribofuranosyl diphosphate (DB01632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-PRP injections
Trial: 32011196
Drug: AA-PRP injections
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-PRP injections
Trial: 34882161
Drug: Healthy dietary
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy dietary pattern (HDP) with 15 g day-1 wolfberries
Trial: 34825898
Drug: Dronabinol (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (5-15 mg/day)
Trial: 32068255
Drug: Original bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Original bortezomib dosing regimen
Trial: 32068255
Drug: Less frequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less frequent bortezomib dosing